Calidi Biotherapeutics Announces Speaker Presentation at ASGCT Conference in Boston on May 14, 2026 Highlighting the RedTail Platform’s Ability to Deliver Genetic Medicines to Distal Sites...
Calidi Biotherapeutics, Inc. (CLDI)
Company Research
Source: GlobeNewswire
SAN DIEGO, April 07, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic medicines, will present new data at the American Society of Gene and Cell Therapy (ASGCT) annual meeting in Boston, Massachusetts on May 14, 2026. The Company will present data on its RedTail platform. RedTail is Calidi’s systemically delivered virotherapy platform designed to selectively target tumors, remodel the tumor microenvironment (TME), and enable high-level expression of therapeutic genetic payloads directly at the tumor site while limiting peripheral exposure. Data presented at the ASGCT meeting by Antonio F. Santidrian, PhD, Chief Scientific Officer and Head of Technical Operations for Calidi, will showcase the ability of the RedTail extracellular enveloped and CD55-overexpressing virus (EEV) to avoid immune clearance, replicate only in target cells, and deliver high concentrat
Show less
Read more
Impact Snapshot
Event Time:
CLDI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CLDI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CLDI alerts
High impacting Calidi Biotherapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
CLDI
News
- Calidi Biotherapeutics to Present New Data on Its Lead Asset CLD-401 at the AACR Annual Meeting in April 2026 [Yahoo! Finance]Yahoo! Finance
- Calidi Biotherapeutics to Present New Data on Its Lead Asset CLD-401 at the AACR Annual Meeting in April 2026GlobeNewswire
- Calidi Biotherapeutics to Present New Data on Its Differentiated Approach to In Situ T-Cell Engagers Including a New Candidate Targeting TROP-2 at the AACR Annual Meeting in April 2026GlobeNewswire
- Research Suggests the Thymus is Critical in Immunotherapy Outcomes [TheStreet.com]TheStreet.com
- Major Discovery Could Reshape Cancer Immunotherapy [TheStreet.com]TheStreet.com
CLDI
Sec Filings
- 4/2/26 - Form 8-K
- 3/31/26 - Form SCHEDULE
- 3/27/26 - Form 10-K
- CLDI's page on the SEC website